Ocusol1%

Ocusol 1% ophthalmic suspension is a corticosteroid indicated for the treatment of steroid-responsive inflammatory conditions of the eye. Its established and guideline-supported uses include:

• Established/approved use: Steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea (ocular), superficial punctate keratitis, herpes zoster keratitis (non-dendritic), iritis, and cyclitis.
• Established/approved use: Selected infective conjunctivitis, when the inherent hazard of steroid use is accepted and an anti-infective agent is co-administered to control the infection.
• Established/approved use: Reduction of inflammation and edema following ocular injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.
• Established/approved use: Management of post-operative inflammation following ophthalmic surgery (e.g. cataract surgery).

Ocusol 1% is not indicated for use in undiagnosed "red eye" without prior ophthalmologic evaluation, since it may mask or worsen an underlying infection.

Each mL of Ocusol 1% ophthalmic suspension contains Ocusol 1% equivalent to 10 mg Ocusol 1% (1% w/v), along with ophthalmic-grade suspending agents, preservative (typically benzalkonium chloride), and buffering agents in a sterile aqueous vehicle.

Ocusol 1% is a synthetic glucocorticoid, formulated as the acetate ester of prednisolone to improve corneal penetration and prolong ocular tissue contact time in a sterile ophthalmic suspension. It is used topically in the eye to suppress inflammation, cellular infiltration, and vascular permeability associated with a variety of ocular inflammatory disorders.

In Bangladesh, Ocusol 1% is marketed exclusively as a 1% ophthalmic suspension in 5 mL dropper bottles. In some other markets, related prednisolone formulations are also available as oral tablets or injections for systemic anti-inflammatory and immunosuppressive use, but the acetate ester form is used almost exclusively as an ophthalmic preparation.

Corticosteroid — Ophthalmic anti-inflammatory agent (glucocorticoid); Ocusol 1% belongs to the topical ocular steroid class.

Ocusol 1% is a glucocorticoid that suppresses the inflammatory response to a variety of inciting agents. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), which control the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid, from membrane phospholipids.

By this mechanism, Ocusol 1% reduces capillary dilation, edema, fibrin deposition, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. The acetate ester form is relatively insoluble, which allows it to penetrate the intact corneal epithelium more effectively than phosphate salt formulations, producing higher intraocular drug concentrations. Systemic absorption after topical ocular administration is minimal under normal use.

For ophthalmic (eye) use only — not for injection or oral use.

• Wash hands thoroughly before use.
• Shake the Ocusol 1% bottle well before each application.
• Tilt the head back, gently pull down the lower eyelid to form a small pocket, and instill the prescribed number of drops without letting the dropper tip touch the eye, eyelid, or any surface, to avoid contamination.
• Close the eye gently for 1–2 minutes and apply light pressure at the inner corner of the eye (nasolacrimal occlusion) to reduce systemic absorption.
• If more than one eye medication is prescribed, wait at least 5 minutes between different eye drop products.
• Remove soft contact lenses before instillation and wait at least 15 minutes before reinserting them, unless directed otherwise by the physician.

Ocusol 1% ophthalmic suspension has minimal systemic absorption with normal use, so clinically significant systemic drug interactions are uncommon. However, the following should be noted:

• Other ophthalmic medications: Concurrent use with other topical eye medications may alter local absorption; space administration of different products by at least 5 minutes.
• Anti-infective agents: When co-administered with topical antibiotics or antivirals for infective conjunctivitis, corticosteroid use can mask signs of worsening infection; close monitoring is required.
• Systemic corticosteroid use (if applicable): In markets where systemic prednisolone formulations are used, standard corticosteroid drug interactions apply, including increased gastrointestinal bleeding risk with NSAIDs, reduced immune response to live vaccines, altered glycemic control with antidiabetic medications, and altered anticoagulant effect with warfarin. These interactions are not typically relevant to the ophthalmic form of Ocusol 1% at recommended doses.

Side effects associated with Ocusol 1% ophthalmic suspension are usually local to the eye and include:

• Transient stinging, burning, or blurred vision immediately after instillation.
• Elevated intraocular pressure (IOP) / steroid-induced glaucoma with prolonged use, which may lead to optic nerve damage and visual field defects.
• Posterior subcapsular cataract formation with long-term use.
• Delayed corneal or scleral wound healing.
• Secondary ocular infection (bacterial, viral, or fungal) due to suppression of the host inflammatory response, or perforation of the globe where thinning of the cornea or sclera exists.
• Mydriasis (pupil dilation) and ptosis (drooping eyelid) have been reported infrequently.

Patients should promptly report eye pain, significant vision changes, or persistent redness to their physician.

Ocusol 1% should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Although systemic absorption after ophthalmic administration is minimal, adequate and well-controlled studies in pregnant women are lacking, and corticosteroids in general have been associated with fetal effects in animal studies at high systemic exposure. A physician should be consulted before use during pregnancy.

It is not known whether topically applied Ocusol 1% is excreted in human milk in clinically significant amounts. Because many systemically absorbed corticosteroids are excreted in breast milk, caution should be exercised and a physician consulted when Ocusol 1% is used by a nursing mother.

Prolonged use of Ocusol 1% can result in elevated intraocular pressure and/or glaucoma, with damage to the optic nerve, defects in visual acuity, and visual field loss; intraocular pressure should be monitored regularly if use extends beyond 10 days.

Ocusol 1% should not be used to treat undiagnosed "red eye," as corticosteroids may mask infection or exacerbate an existing untreated ocular infection. Use in the presence of thinning of the cornea or sclera may lead to perforation. Prolonged use may also suppress the host immune response, increasing the risk of secondary ocular infections; the possibility of fungal infection should be considered in any persistent corneal ulceration where a corticosteroid has been used.

Use with caution in patients with a history of herpes simplex keratitis, as corticosteroids may prolong the course and exacerbate the severity of the infection. Employ the lowest effective dose for the shortest duration necessary, and taper gradually rather than stopping abruptly. Reassess the patient if there is no improvement after 2 days of therapy.

Ophthalmic overdose of Ocusol 1% is unlikely to cause acute systemic toxicity, but excessive or prolonged use increases the risk of elevated intraocular pressure, glaucoma, and cataract formation. If a large amount is accidentally ingested or instilled excessively, or if the eye is exposed to a non-ophthalmic concentrated form, flush the eye gently with clean water and seek immediate medical attention or contact a poison control center. Do not attempt to manage a suspected overdose with home remedies; professional medical evaluation is advised in all cases of suspected overdose or accidental ingestion.

Store Ocusol 1% ophthalmic suspension at room temperature (below 30°C), away from light and moisture. Keep the bottle tightly closed, shake well before each use, and keep out of reach of children. Discard any unused portion 4 weeks after opening, or as directed on the label.

Pediatric patients: Safety and efficacy of Ocusol 1% in pediatric patients have not been extensively established through controlled trials; when used in children, close monitoring for elevated intraocular pressure is recommended, as children may be more sensitive to steroid-induced ocular hypertension with long-term use.

Elderly patients: No overall differences in safety or effectiveness have been reported between elderly and younger adult patients; standard adult dosing generally applies with routine monitoring.

Renal/hepatic impairment: No dose adjustment of ophthalmic Ocusol 1% is established as necessary in renal or hepatic impairment, given minimal systemic absorption; however, caution is still advised and a physician should be consulted.

The duration of treatment with Ocusol 1% depends on the severity of the inflammatory condition and clinical response, and should be determined by the prescribing physician. Treatment is typically continued for 1 to 2 weeks for mild conditions, and may extend to several weeks for more severe or post-surgical inflammation, with the dose tapered gradually rather than stopped abruptly. Use beyond 10 days requires monitoring of intraocular pressure. If no improvement is seen within 2 days, the patient should be reassessed by a physician.

Corticosteroids; Glucocorticoids; Topical ophthalmic anti-inflammatory agents — Ocusol 1% is classified within this group.

Ocusol 1% exerts its anti-inflammatory effect by inducing lipocortin (phospholipase A2 inhibitory protein) synthesis, which blocks the release of arachidonic acid from membrane phospholipids. This reduces downstream production of prostaglandins and leukotrienes, the key mediators of inflammation, thereby decreasing capillary dilation, vascular permeability, leukocyte migration, and fibroblast and collagen deposition in ocular tissue.

C

The safety and efficacy of Ocusol 1% ophthalmic suspension in pediatric patients have not been established through extensive controlled clinical trials. When prescribed for a child, it should be used at the lowest effective dose for the shortest duration necessary, under close physician supervision, with regular monitoring of intraocular pressure, since prolonged corticosteroid use may carry a higher risk of ocular hypertension and growth-related effects in children. Ocusol 1% should only be used in children when a physician determines the potential benefit outweighs the risk.